Newsroom
  • Press Releases
  • Presentations
Investors
  • Overview
  • Annual Meeting of Stockholders
  • Warrant Exercise Inquiries
  • Restricted Stock Inquiries
  • News / Events
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
Contact

CytoDyn Inc.

  • Home
  • About CytoDyn
    • Meet CytoDyn
  • Our Science
  • Pipeline
    • Overview
    • HIV
    • Cancer
    • COVID-19
  • Our Team
    • Management Team
    • Board of Directors
  • Publications
  • Scientific Advisory Board
  • Newsroom
  • Investors
  • Contact
Latest News

IMPORTANT CORRECTION OF INVESTIGATIONAL DRUG INFORMATION

On February 11, 2022, CytoDyn, Inc. received a Warning Letter from the U.S. Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion in which FDA asserted that statements made in a video created a misleading impression regarding the safety and efficacy of leronlimab.  Leronlimab is an investigational drug that has not been approved (or authorized) by the U.S. FDA for the treatment of COVID-19 or for any indication.  For more information, click here to access a Dear Healthcare Provider (DHCP) Letter: View Here.

Publications

Infectious Diseases Society of America: Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome

Infectious Diseases Society of America: Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome

Apr 22, 2022
PLOS Pathogens: Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species

PLOS Pathogens: Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species

Mar 31, 2022
Frontiers in Immunology: CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab

Frontiers in Immunology: CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab

Nov 19, 2021
Nature Communications: Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission

Nature Communications: Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission

Jun 7, 2021
Journal of Translational Autoimmunity: Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab

Journal of Translational Autoimmunity: Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab

Mar 16, 2021
Springer Nature: Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy

Springer Nature: Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy

Jan 23, 2021
Journal of Translational Autoimmunity: Disruption of CCR5 Signaling to Treat COVID-19-Associated Cytokine Storm: Case Series of Four Critically Ill Patients Treated with Leronlimab

Journal of Translational Autoimmunity: Disruption of CCR5 Signaling to Treat COVID-19-Associated Cytokine Storm: Case Series of Four Critically Ill Patients Treated with Leronlimab

Dec 30, 2020
International Journal of Infectious Diseases: CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14

International Journal of Infectious Diseases: CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14

Oct 30, 2020
Infectious Diseases Society of America: Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab

Infectious Diseases Society of America: Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab

Oct 20, 2020
National Library of Medicine: PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry null Mice

National Library of Medicine: PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry null Mice

Feb 24, 2018
RSS
  • 1
  • 2
  • Next »
© 2022 CytoDyn Inc. All Rights Reserved.
  • Twitter
  • Facebookj
Privacy Policy Disclaimer Sitemap